Jazz Pharmaceuticals Increases Guidance Based On GW Pharma Acquisition
Cannabis Law Report
JUNE 17, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. net leverage by the end of 2022.
Let's personalize your content